The Oncogenomics Handbook

  • William J. LaRochelle
  • Richard A. Shimkets

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xvii
  2. Genomics, Cancer Targets, Transcriptomics, and Gene Expression Analysis

    1. Front Matter
      Pages 1-1
    2. Xuefeng Bruce Ling, Gene Cutler, Timothy Hoey
      Pages 3-17
    3. Tapan K. Bera, Kristi A. Egland, B. K. Lee, Ira Pastan
      Pages 31-42
    4. Balanehru Subramanian, Alexander Nakeff, Frederick Valeriote
      Pages 53-67
    5. Sarah S. Williams, Bruce J. Aronow, Susanne I. Wells
      Pages 69-88
  3. Advances in Proteomic and Enzymatic Cancer-Profiling Technologies

    1. Front Matter
      Pages 89-89
    2. Chen Xu, John R. Yates III
      Pages 91-107
    3. Douglas A. Jeffery, Amos Baruch, Matthew Bogyo
      Pages 109-122
    4. John R. Griffiths, Marion Stubbs
      Pages 135-149
  4. Cancer Target Validation: Cellular Approaches

    1. Front Matter
      Pages 165-165
    2. Mustapha Diallo, Katja Schmitz, Ute Schepers
      Pages 167-193
    3. Kris F. Sachsenmeier, Jonathan A. Terrett
      Pages 195-207
    4. David Ljungman, James C. Cusack Jr.
      Pages 209-228
    5. Bharvin K. R. Patel
      Pages 229-244
  5. Cancer Target Validation: Animal Approaches

    1. Front Matter
      Pages 245-245

About this book

Introduction

Bioinformatic integration of the findings from recent genomic and proteomic research has made possible the development of highly selective therapeutics that can target specific cellular pathways controlling cell proliferation, differentiation, metastasis, evasion of immune surveillance, angiogenesis, and apoptosis. In The Oncogenomics Handbook, a panel of internationally recognized researchers and clinicians provides an integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following that path, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including rituximab, Herceptin®, Avastin™, ABGX-EGF, Velcade®, Iressa®, and Zevalin® are addressed. Additional chapters review clinical diagnostics, bioanalytics, and biomarkers and their importance to therapeutic outcome; detail antiangiogenic, supportive, immunomodulatory, and tumor-targeted approaches to cancer therapy; and provide a systems biology-bioinformatics overview of strategies and initiatives for the postgenomic era. Highlights include cancer genomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.
Authoritative and state-of-the-art, The Oncogenomics Handbook offers cancer researchers and drug developers a comprehensive update on the contribution of the genomic revolution to cancer drug discovery and development.

Keywords

apoptosis carcinoma classification diagnostics imaging senescence

Editors and affiliations

  • William J. LaRochelle
    • 1
  • Richard A. Shimkets
    • 1
  1. 1.CuraGen CorporationNew Haven

Bibliographic information

  • DOI https://doi.org/10.1385/1592598935
  • Copyright Information Humana Press Inc. 2005
  • Publisher Name Humana Press
  • eBook Packages Medicine
  • Print ISBN 978-1-58829-425-8
  • Online ISBN 978-1-59259-893-9
  • About this book
Industry Sectors
Biotechnology
Pharma